DCM
IMVT icon

DME Capital Management’s Immunovant IMVT Stock Holding History

DME Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Buy
+93,520
New +$2.42M 0.07% 41

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

DME Capital Management's IMVT Position: Q1 2026 in Review

DME Capital Management opened a new position in Immunovant (IMVT) in Q1 2026: 93,520 shares worth $2.32M. The stake represents 0.07% of the portfolio and ranks #41 among its holdings.

215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • DME Capital Management held 93,520 shares of Immunovant worth $2.32M as of Q1 2026.
  • Immunovant was a new DME Capital Management position in Q1 2026.
  • Immunovant made up 0.07% of DME Capital Management's portfolio in Q1 2026, its #41 holding.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on DME Capital Management's 13F filing for Q1 2026, filed 15 May 2026.